Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Natural product inhibitors of Hsp90: potential leads for drug discovery.

Amolins MW, Blagg BS.

Mini Rev Med Chem. 2009 Feb;9(2):140-52. Review.

2.

Natural Product Inspired N-Terminal Hsp90 Inhibitors: From Bench to Bedside?

Khandelwal A, Crowley VM, Blagg BS.

Med Res Rev. 2016 Jan;36(1):92-118. doi: 10.1002/med.21351. Epub 2015 May 25. Review.

3.

Targeting heat-shock-protein 90 (Hsp90) by natural products: geldanamycin, a show case in cancer therapy.

Franke J, Eichner S, Zeilinger C, Kirschning A.

Nat Prod Rep. 2013 Oct 11;30(10):1299-323. doi: 10.1039/c3np70012g. Epub 2013 Aug 12. Review.

PMID:
23934201
4.

Using natural product inhibitors to validate Hsp90 as a molecular target in cancer.

Neckers L.

Curr Top Med Chem. 2006;6(11):1163-71. Review.

PMID:
16842153
5.

Purine-scaffold Hsp90 inhibitors.

Taldone T, Chiosis G.

Curr Top Med Chem. 2009;9(15):1436-46. Review.

6.

Structure-based and in silico design of Hsp90 inhibitors.

Sgobba M, Rastelli G.

ChemMedChem. 2009 Sep;4(9):1399-409. doi: 10.1002/cmdc.200900256. Review.

PMID:
19685544
7.

Discovery and development of pyrazole-scaffold Hsp90 inhibitors.

McDonald E, Jones K, Brough PA, Drysdale MJ, Workman P.

Curr Top Med Chem. 2006;6(11):1193-203. Review.

PMID:
16842156
8.

Ansamycin inhibitors of Hsp90: nature's prototype for anti-chaperone therapy.

Porter JR, Ge J, Lee J, Normant E, West K.

Curr Top Med Chem. 2009;9(15):1386-418. Review.

PMID:
19860734
9.

Geldanamycin, radicicol, and chimeric inhibitors of the Hsp90 N-terminal ATP binding site.

Hadden MK, Lubbers DJ, Blagg BS.

Curr Top Med Chem. 2006;6(11):1173-82. Review.

PMID:
16842154
10.

Heat shock protein 90 inhibitors as therapeutic agents.

Gomez-Monterrey I, Sala M, Musella S, Campiglia P.

Recent Pat Anticancer Drug Discov. 2012 Sep;7(3):313-36. Review.

PMID:
22338602
11.
12.

Natural products in structure-assisted design of molecular cancer therapeutics.

Pfisterer PH, Wolber G, Efferth T, Rollinger JM, Stuppner H.

Curr Pharm Des. 2010 May;16(15):1718-41. Review.

PMID:
20222854
13.

Heat-shock protein 90 inhibitors as antitumor agents: a survey of the literature from 2005 to 2010.

Messaoudi S, Peyrat JF, Brion JD, Alami M.

Expert Opin Ther Pat. 2011 Oct;21(10):1501-42. doi: 10.1517/13543776.2011.594041. Epub 2011 Jun 21. Review.

PMID:
21689065
14.

Drug-mediated targeted disruption of multiple protein activities through functional inhibition of the Hsp90 chaperone complex.

Stravopodis DJ, Margaritis LH, Voutsinas GE.

Curr Med Chem. 2007;14(29):3122-38. Review.

PMID:
18220746
15.

Natural Product Kongensin A is a Non-Canonical HSP90 Inhibitor that Blocks RIP3-dependent Necroptosis.

Li D, Li C, Li L, Chen S, Wang L, Li Q, Wang X, Lei X, Shen Z.

Cell Chem Biol. 2016 Feb 18;23(2):257-66. doi: 10.1016/j.chembiol.2015.08.018. Epub 2016 Jan 28.

16.

Alternate strategies of Hsp90 modulation for the treatment of cancer and other diseases.

Brandt GE, Blagg BS.

Curr Top Med Chem. 2009;9(15):1447-61. Review.

17.

Discovery and development of heat shock protein 90 inhibitors as anticancer agents: a review of patented potent geldanamycin derivatives.

Kim T, Keum G, Pae AN.

Expert Opin Ther Pat. 2013 Aug;23(8):919-43. doi: 10.1517/13543776.2013.780597. Epub 2013 May 4. Review.

PMID:
23641970
18.

Towards the discovery of drug-like epigallocatechin gallate analogs as Hsp90 inhibitors.

Bhat R, Adam AT, Lee JJ, Gasiewicz TA, Henry EC, Rotella DP.

Bioorg Med Chem Lett. 2014 May 15;24(10):2263-6. doi: 10.1016/j.bmcl.2014.03.088. Epub 2014 Apr 4.

PMID:
24745965
19.

Development and application of Hsp90 inhibitors.

Solit DB, Chiosis G.

Drug Discov Today. 2008 Jan;13(1-2):38-43. doi: 10.1016/j.drudis.2007.10.007. Epub 2007 Nov 26. Review.

PMID:
18190862
20.

Purine-scaffold Hsp90 inhibitors.

Chiosis G, Tao H.

IDrugs. 2006 Nov;9(11):778-82.

PMID:
17096299

Supplemental Content

Support Center